国泰海通证券股份有限公司 关于晋拓科技股份有限公司 首次公开发行限售股上市流通事项的核查意见 限公司首次公开发行股票的批复》（证监许可20221381 号）核准，晋拓科技股 份有限公司（以下简称"公司"）首次公开发行人民币普通股（A 股）6,795.20 万股，并于 2022 年 7 月 25 日在上海证券交易所上市。本次发行证券已于 2022 年 7 月 25 日在上海证券交易所上市。国泰海通证券股份有限公司（以下简称"保 荐机构"或"国泰海通"）担任其持续督导保荐机构，持续督导期间为 2022 年 根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》 等有关法律、法规要求，国泰海通作为公司首次公开发行股票并上市的持续督导 保荐机构，对公司首次公开发行限售股上市流通事项进行了专项核查，现将本次 核查的情况报告如下： 限公司首次公开发行股票的批复》（证监许可20221381 号）核准，晋拓科技股 份有限公司（以下简称"公司"）首次公开发行人民币普通股（A 股）6,795.20 万 股，并于 2022 年 7 月 25 日在上海证券交易所上市。 本次上市流通的限售股为公司首次公开发行限售股，限售期 ...

Summary of Key Points Core Viewpoint - The company, Shenzhen Minglida Precision Technology Co., Ltd., has decided to postpone certain fundraising investment projects due to market changes and operational needs, reallocating part of the raised funds to a new project in Mexico [1][10]. Group 1: Fundraising Overview - The company issued 10 million convertible bonds with a total face value of 1 billion yuan, netting approximately 991.61 million yuan after deducting issuance costs [1]. - The funds are managed in a dedicated account with strict regulatory oversight, ensuring compliance with relevant laws and regulations [5][11]. Group 2: Investment Projects - The original investment projects included the construction of precision component production bases in Anhui and Jiangxi, and a smart manufacturing project for key components [3]. - The company plans to redirect 45 million yuan (45% of total raised funds) from the postponed projects to a new project for constructing a precision component production base for electric vehicles in Mexico [4][10]. Group 3: Project Postponement Details - The project for the Jiangxi precision component production base will experience delays in reaching its operational status due to various market and operational factors [9][10]. - The postponement does not alter the investment amounts or project content, ensuring no adverse impact on shareholder interests [10][12]. Group 4: Compliance and Oversight - The company has followed necessary procedures for the project postponement, receiving approval from both the board of directors and the supervisory board [11][12]. - The sponsor, Guotai Junan Securities, has confirmed that the postponement complies with regulatory requirements and does not harm the company's or shareholders' interests [12].

根据中银国际证券股份有限公司（以下简称"本公司"）与国泰海通证券股份有限公司签署的相关协议， 自2025年7月18日起，投资者可在国泰海通证券股份有限公司办理本公司旗下交易型开放式指数证券投 资基金的申购、赎回代办业务。现将有关事项公告如下： 一、适用基金及业务范围 ■ 自2025年7月18日起，投资者可通过国泰海通证券股份有限公司办理上述基金份额的申购、赎回等业 务。 1、国泰海通证券股份有限公司 客服电话：95521 网址：www.gtht.com 二、重要提示 上述适用基金的申购、赎回等业务仅适用于处于正常开放期时的基金，基金特殊期间的有关规定详见对 应基金的基金合同和招募说明书等相关法律文件及本公司发布的最新业务公告。 三、投资者可通过以下途径咨询有关详情： 本公告的解释权归中银国际证券股份有限公司所有。 特此公告 网址： www.bocifunds.com 四、风险提示： 投资者在上述证券公司办理本基金的投资事务，具体办理规则及程序请咨询相应申购赎回代理券商的规 定。本公司承诺以诚实信用、勤勉尽责的原则管理和运用基金资产，但不保证基金一定盈利，也不保证 最低收益。基金的过往业绩及其净值高低并不预示其 ...

Core Viewpoint - Hanhigh Group Co., Ltd. is planning to conduct an initial public offering (IPO) of its shares and list on the main board in China, with strategic placement involving its senior management and core employees participating through a dedicated asset management plan [1][2][3]. Approval and Authorization - The board of directors and the shareholders' meeting of Hanhigh Group have approved the application for the IPO of RMB ordinary shares (A shares) [2][3]. - The Shenzhen Stock Exchange and the China Securities Regulatory Commission have reviewed and approved the IPO, confirming that Hanhigh Group meets the issuance and listing conditions [2][3]. Strategic Placement Details - The total number of shares to be publicly issued is 40.01 million, accounting for 10% of the total shares post-issuance, with no existing shareholders selling shares [2][3]. - The initial strategic placement amount is set at 4.001 million shares, which is 10% of the total issuance, with a maximum subscription amount of RMB 75 million [3][4]. Participants in Strategic Placement - The strategic placement will involve a dedicated asset management plan established by Hanhigh Group's senior management and core employees, named "Junxiang 1 Asset Management Plan" [3][5]. - The participants in the Junxiang 1 Asset Management Plan include senior management and core employees of Hanhigh Group, with the total investment amounting to RMB 75 million [5][11]. Compliance and Regulations - The selection criteria for strategic placement investors comply with relevant regulations, ensuring that the number of investors does not exceed 10 and that the placement does not exceed 20% of the total issuance [4][5]. - The lock-up period for shares acquired through the strategic placement is set at 12 months from the date of listing [4][14]. Legal and Regulatory Review - The legal counsel for the main underwriter has confirmed that the selection standards and qualifications for strategic placement investors are in accordance with applicable laws and regulations [15]. - The underwriter has also verified that there are no prohibitive conditions as outlined in the regulations regarding the strategic placement of shares [15].

Core Viewpoint - The event "Rational Investment Accompanying Me - Entering the Listed Company Jilin Aodong" aims to enhance communication between investors and the company, promoting rational, value, and long-term investment concepts [1] Group 1: Company Overview - Jilin Aodong has been recognized as a leading company in the Chinese pharmaceutical industry, ranking among the top 100 pharmaceutical companies in China for 11 consecutive years and awarded as one of the 500 most valuable brands in China [1][2] - The company has transformed from a state-owned deer farm to a publicly listed pharmaceutical company, expanding its business into various fields including traditional Chinese medicine, chemical drugs, health products, and food [2][3] - Jilin Aodong's product portfolio includes well-known products such as Anshen Bnnao Liquid and Xiaoer Chaigui Fever Oral Liquid, supported by a robust product hierarchy aimed at driving performance growth [2][3] Group 2: Business Strategy and Financial Performance - The company operates with a "pharmaceutical + finance + health" multi-wheel drive strategy, leveraging financial investments to enhance its core pharmaceutical business and extend its reach into biopharmaceuticals and internet healthcare [3] - Jilin Aodong holds 628 production approval numbers, with over 300 for both traditional Chinese medicine and chemical drugs, indicating a strong regulatory compliance and product diversity [3] - The company plans to maintain a stable dividend policy, with potential increases as operational performance improves, and is actively working on enhancing sales in its enzyme product line and chain pharmacy profitability [4] Group 3: Investor Engagement and Future Outlook - The event facilitated direct interaction between investors and the company's management, allowing for discussions on dividend policies, product sales, and profitability of chain pharmacies [4] - The company aims to continue its commitment to innovation and responsibility, striving for a more prosperous future while contributing to the development of the Chinese pharmaceutical industry [5]

Core Viewpoint - The article discusses the qualification review conducted by Guotai Junan Securities Co., Ltd. regarding the share transfer of Shanghai Yizhong Pharmaceutical Co., Ltd. from its shareholder Shanghai Kaibao Pharmaceutical Co., Ltd. to specific institutional investors [1][2]. Group 1: Share Transfer Process - Guotai Junan was entrusted by Shanghai Kaibao to organize the inquiry transfer of shares before the initial public offering of Shanghai Yizhong [1]. - The inquiry transfer is conducted in accordance with relevant regulations, including the implementation opinions for the establishment of the Sci-Tech Innovation Board and the trial registration system [1]. Group 2: Qualification Review - Guotai Junan completed the qualification review of the transferor, which included interviews and inquiries, as well as the collection of relevant documents [1][2]. - The review confirmed that Shanghai Kaibao is a legally existing joint-stock company without any circumstances that would lead to its termination under national laws and regulations [2][3]. Group 3: Compliance with Regulations - The review found that Shanghai Kaibao does not fall under any prohibited circumstances outlined in the inquiry transfer and allocation guidelines, such as violations of share reduction regulations or other commitments [3][4]. - The transferor's shares are confirmed to be pre-IPO shares without any restrictions such as pledges or judicial freezes [4].

Core Viewpoint - M&G Investments has signed a strategic cooperation memorandum with Guotai Junan Securities to provide more global market investment opportunities for Chinese investors [1][3] Group 1: Cooperation Focus Areas - The collaboration will focus on four key areas: information sharing, asset management, client services, and investment market promotion [3] - The partnership aims to leverage M&G's global investment expertise and Guotai Junan's local market advantages to capitalize on the rapid growth of China's asset management market [3] Group 2: Market Potential - M&G anticipates that by 2030, the scale of China's asset management industry will reach $40.4 trillion [3] Group 3: M&G's Regional Strategy - M&G has been active in the Asian investment market for nearly 20 years, serving a diverse client base including sovereign wealth funds, pension funds, insurance companies, private banks, and retail investors [3] - As part of its regional growth strategy, M&G is enhancing its investment portfolio management and distribution capabilities in Hong Kong to support cross-border investment solutions [3] Group 4: Joint Initiatives - The two companies are currently developing a joint brand fixed income investment solution focused on the Asian market, which is expected to launch in the coming months [3] - They are also exploring other collaborative projects, including QDII-qualified products, investment consulting, and product sales cooperation mechanisms to maximize their strengths in global investment management, local market knowledge, and client services [3]

变更后签字人员的基本情况： 张莉律师毕业于南京大学、清华大学，已获得中国律师执业资格，主要从事 资本市场、投融资等方面的业务，先后参与并完成了多家企业的股份制改组、股 票发行与上市、增发等证券法律业务。 徐定辉律师毕业于东北大学、复旦大学，已获得中国律师资格，主要从事资 本市场、投融资等方面的业务，先后参与并完成了多家企业的股份制改组、股票 发行与上市、增发等证券法律业务。 张莉律师、徐定辉律师同意承担签字律师职责，履行尽职调查义务，承诺对 刘攀律师签署的相关文件均予以认可并承担相应法律责任，并对今后签署材料的 真实性、准确性、完整性承担相应法律责任。 本公司对张莉律师、徐定辉律师出具的专项报告进行复核，认为张莉律师、 徐定辉律师已履行尽职调查义务，并出具专业意见，且与刘攀律师的结论性意见 一致。 国泰海通证券股份有限公司关于嘉泽新能源股份有限公司 向特定对象发行股票项目变更签字律师的专项说明 上海证券交易所： 基本情况：嘉泽新能源股份有限公司（以下简称"发行人"）于 2025 年 2 月 13 日向贵所提交向特定对象发行股票的申请，于 2025 年 2 月 21 日被受理。 本公司作为保荐人承担本次发行的保 ...

Core Viewpoint - The company is implementing a differentiated dividend distribution plan, which includes a cash dividend of 2.55 RMB per 10 shares, while excluding shares held in the repurchase account from profit distribution [2][4]. Group 1: Reasons for Differentiated Dividend - The company held a board meeting on April 24, 2024, to approve a share repurchase plan, with a total repurchase amount not less than a specified amount per share, aimed at employee stock ownership plans or equity incentives [1]. - The repurchase price cap was adjusted from 23 RMB to 22.76 RMB per share, effective June 14, 2024, with a total of 6,124,910 shares repurchased by April 7, 2025 [1]. Group 2: Dividend Distribution Plan - The company plans to distribute a cash dividend of 2.55 RMB per 10 shares (tax included) to all shareholders, with no capital reserve transfer or bonus shares [2]. - The total share capital is 409,861,106 shares, and after excluding the repurchased shares, the base for calculating the cash dividend is 403,736,196 shares, resulting in a total cash dividend distribution of approximately 102,952,729.98 RMB (tax included) [2]. Group 3: Calculation Basis for Dividend - The profit distribution will be based on the total share capital minus the shares held in the repurchase account as of the equity registration date [2]. - The cash dividend per share is calculated as approximately 0.251 RMB per share, based on the formula provided [3]. Group 4: Impact on Ex-Dividend Price - The ex-dividend reference price is calculated as (previous closing price - cash dividend) / (1 + change in circulating shares ratio), with the circulating shares ratio being 0 due to no changes in circulating shares [3][4]. - The calculated ex-dividend reference price is approximately 17.215 RMB per share, based on the previous closing price of 17.47 RMB [4][5]. Group 5: Verification by Sponsoring Institutions - The sponsoring institutions have verified that the differentiated dividend distribution complies with relevant laws and regulations, and does not harm the interests of the company or its shareholders [5].

Group 1 - The company has raised a total of RMB 1,806,856,851.88 through the issuance of 24,860,441 shares at a price of RMB 72.68 per share, with a net amount of RMB 1,780,262,125.56 after deducting issuance costs [1][2] - The raised funds are allocated for projects in the AIGC and smart mobility sectors, with a total investment of RMB 180,815.69 million, of which RMB 180,685.69 million is planned to be funded by the raised capital [2][3] - The company has pre-invested RMB 38,453.54 million of its own funds into the projects from December 22, 2023, to May 31, 2025, and plans to replace this with the raised funds [2][4] Group 2 - The company has incurred issuance costs totaling RMB 2,659.47 million, of which RMB 416.01 million was paid from its own funds prior to the capital being raised, and it intends to replace this amount with the raised funds [4][5] - The board of directors has approved the use of raised funds to replace pre-invested self-raised funds and issuance costs, confirming that this does not alter the intended use of the funds or harm shareholder interests [6][7] - The independent auditor, Deloitte, has verified the pre-invested funds and issuance costs, confirming compliance with relevant regulations and reflecting the actual expenditures accurately [7][8]